NEW YORK (GenomeWeb News) – Compugen said today it will collaborate with Merck to predict and validate peptides that are likely to activate G-protein coupled receptors that Merck could use in its drug development programs.
 
The agreement, which Compugen said is its first such peptide collaboration, includes an option that would grant Merck exclusive worldwide licenses to develop and market these peptides.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

A new estimate places the last universal common ancestor to life on Earth as living 3.9 billion years ago, Inverse reports.

23andMe's Anne Wojcicki ponders DNA and what it means to be human in a New York Times essay.

In PNAS this week: retinitis pigmentosa gene therapy, role of microbiome in growth stunting, and more.

Bloomberg reports that researchers and drug companies are modeling anti-obesity treatments after the rare genetic condition essential fructosuria.